Pregnancy and Autoimmune Disorders: Implications for Maternal and Fetal Health
Keywords:
pregnancy, autoimmune disease, maternal health, fetal outcomes, immunological adaptation, obstetric complications, neonatal immunity, immunosuppressive therapyAbstract
Autoimmune disorders represent a heterogeneous group of chronic conditions
characterized by dysregulated immune responses directed against self-antigens. These diseases
frequently affect women of reproductive age, making pregnancy management clinically significant.
Gestation induces complex immunological, hormonal, and metabolic adaptations that may alter disease
activity, influence obstetric outcomes, and affect fetal development. Certain disorders improve in
pregnancy; others are quiescent or exaggerated and confer an increased risk of complications including
preeclampsia, preterm labour, fetal growth restriction and neonatal immune sequelae [4, 5]. Timely
assessment and stratification of risks, multidisciplinary follow up and differentiation in treatment
planning based on maternal stability and fetal safety represent crucial steps. In this article,
immunopathological mechanisms, clinical features, management principles and outcomes related to
autoimmune diseases in pregnant patients are reviewed with a focus on evidence-based approaches to
minimize morbidity and mortality. Pregnancy in the context of autoimmune disorders is a clinically
challenging dilemma because these patient groups experience unique immunological, hormonal and
vascular adaptations which affect disease course and obstetric outcomes. Autoimmune disorders like
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), antiphospholipid syndrome,
autoimmune thyroid disease, and multiple sclerosis can show a variable response to pregnancy with
respect to remission, exacerbation, or unpredictable fluctuation during pregnancy and in the postpartum
period. Maternal immune tolerance of the semi-allogeneic fetus necessitates precise immunomodulation
that can affect autoantibody production and inflammatory pathways. Such changes may alter placental
function leading to miscarriage, preeclampsia, fetal growth restriction, preterm birth and neonatal
complications. Maternal and neonatal prognosis depends on early diagnosis, preconception counseling,
multidisciplinary monitoring, and individualized pharmacotherapy. In this article, we will overview
immunopathophysiological viral mechanisms, clinical features, diagnostic protocols and recent
management strategies to ensure the best possible clinical outcomes for the mother and child. Type
autoimmune diseases predominantly first run into women during their reproductive years and pose
considerable clinical challenges when they overlap with pregnancy. Mechanistic processes that underlay these physiological adaptations contributing to fetal tolerance include modulation of innate and adaptive
immunity, endocrine adaptations, and vascular remodeling. Such modifications may change the
trajectory of disease by either dampening levels of inflammatory activity or precipitating exacerbations
in accordance with the immunopathology that underpins the chronic lung disease process. Dysregulated
immune mechanisms, including maternal autoantibodies, systemic inflammation, and endothelial
dysfunction, can disrupt placentation and fetal growth. Pregnancy syndrome with a high level of disease
control leads to outcomes such as hypertensive disorders of pregnancy and preterm birth, intrauterine
growth restriction and transitioning neonatal immune changes with high frequency. Nevertheless, well
planned conception, suitable medical interventions, and organized follow-up dramatically enhance
outcomes. Modern-day validation reinforces the continued necessity of immunologic quietude, as well
as avoiding exacerbations, and safe therapeutic exposure in both pregnancy and the postpartum period.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
A. Smyth, G. H. M. Oliveira, B. D. Lahr, K. R. Bailey, S. M. Norby, и V. D. Garovic, «A
systematic review and meta-analysis of pregnancy outcomes in patients with chronic kidney
disease», Annals of Internal Medicine, т. 152, вып. 9, сс. 577–585, 2010, doi: 10.7326/0003
4819-152-9-201005040-00007.
A. Tincani, C. Nalli, J. Khizroeva, V. Bitsadze, L. Andreoli, и A. Makatsariya, «Autoimmune
diseases and pregnancy», Best Practice & Research Clinical Obstetrics and Gynaecology, т. 60,
сс. 34–45, 2019, doi: 10.1016/j.bpobgyn.2019.04.007.
J. P. Buyon, R. M. Clancy, и D. M. Friedman, «Autoimmune-associated congenital heart block:
integration of clinical and research clues in the management of the maternal/foetal dyad»,
Journal of Clinical Investigation, т. 119, вып. 11, сс. 3462–3469, 2009, doi: 10.1172/JCI39585.
J. H. Barrett, P. Brennan, M. Fiddler, и A. J. Silman, «Does rheumatoid arthritis remit during
pregnancy and relapse postpartum?», Arthritis & Rheumatism, т. 42, вып. 6, сс. 1219–1227,
1999, doi: 10.1002/1529-0131(199906)42:6%3C1219::AID-ANR19%3E3.0.CO;2-G.
L. Andreoli и др., «EULAR recommendations for women’s health and the management of
family planning, assisted reproduction, pregnancy and menopause in patients with systemic
lupus erythematosus and/or antiphospholipid syndrome», Annals of the Rheumatic Diseases, т.
76, вып. 3, сс. 476–485, 2017, doi: 10.1136/annrheumdis-2016-209770.
E. F. Chakravarty, I. Colón, E. S. Langen, D. A. Nix, Y. Y. El-Sayed, и M. C. Genovese,
«Factors that predict prematurity and preeclampsia in pregnancies that are complicated by
systemic lupus erythematosus», American Journal of Obstetrics and Gynecology, т. 192, вып. 6,
сс. 1897–1904, 2005, doi: 10.1016/j.ajog.2005.02.063.
M. E. B. Clowse, «Lupus activity in pregnancy», Rheumatic Disease Clinics of North America,
т. 33, вып. 2, сс. 237–252, 2007, doi: 10.1016/j.rdc.2007.01.002.
A. Lateef и M. Petri, «Managing lupus patients during pregnancy», Best Practice & Research
Clinical Rheumatology, т. 27, вып. 3, сс. 435–447, 2013, doi: 10.1016/j.berh.2013.07.005.
M. D. Lockshin и др., «Prediction of adverse pregnancy outcome in patients with lupus: results
from the PROMISSE study», Annals of Internal Medicine, т. 157, вып. 12, сс. 716–724, 2012,
doi: 10.7326/0003-4819-157-10-201211200-00004.
[10] L. R. Sammaritano, «Pregnancy in patients with autoimmune diseases», Rheumatic Disease
Clinics of North America, т. 43, вып. 2, сс. 189–205, 2017, doi: 10.1016/j.rdc.2016.12.004.
[11] I. C. Saulescu, N. Gica, A. M. Panaitescu, G. Peltecu, и C. Gica, «Preparing for pregnancy in
women with systemic lupus erythematosus—A multidisciplinary approach», Journal of Clinical
Medicine, т. 11, вып. 19, с. 5668, 2022, doi: 10.3390/jcm11195668.
[12] D. S. Dalal, K. A. Patel, и A. Shahane, «Systemic lupus erythematosus and pregnancy: A brief
review», Journal of Obstetrics and Gynaecology of India, т. 69, вып. 2, сс. 104–109, 2019, doi:
10.1007/s13224-018-1183-0.
[13] A. Gerede и others, «Systemic lupus erythematosus in pregnancy: Clinical challenges and
management», Rheumatology International, т. 45, вып. 1, сс. 1–12, 2025, doi: 10.1007/s00296
024-05678-0.
[14] M. Østensen и F. Förger, «Treatment with immunosuppressive and disease modifying drugs
during pregnancy and lactation», Nature Reviews Rheumatology, т. 5, вып. 7, сс. 382–390,
2009, doi: 10.1038/nrrheum.2009.91.
[15] G. R. de Jesus, C. Mendoza-Pinto, N. R. de Jesus, F. C. dos Santos, и E. M. Klumb,
«Understanding and managing pregnancy in patients with lupus», Autoimmune Diseases, т.
2015, с. 943490, 2015, doi: 10.1155/2015/943490.
